Researchers have established a baseline set of injectable hydrogels that show promise to help heal wounds, deliver drugs, and treat cancer.
Critically, they’ve analyzed how the chemically distinct hydrogels provoke the body’s inflammatory response—or not.
The researchers designed the hydrogels to be injectable and create a mimic of cellular scaffolds in a desired location. They serve as placeholders while the body naturally feeds new blood vessels and cells into the scaffold, which degrades over time to leave natural tissue in its place. Hydrogels can also carry chemical or biological prompts that determine the scaffold’s structure or affinity to the surrounding tissue.
“We don’t want zero inflammation; we want appropriate inflammation.”
The study demonstrates it should be possible to tune multidomain peptide hydrogels to produce appropriate inflammatory response for what they’re treating.
“We’ve been working on peptide-based hydrogels for a number of years and have produced about 100 different types,” says Jeffrey Hartgerink, a chemist and bioengineer at Rice University. “In this paper, we wanted to back up a bit and understand some of the fundamental ways in which they modify biological environments.”
The researchers wanted to know specifically how synthetic hydrogels influence the environment’s inflammatory response. The two-year study offered the first opportunity to test a variety of biocompatible hydrogels for the levels of inflammatory response they trigger.
“Usually, we think of inflammation as bad,” Hartgerink says. “That’s because inflammation is sometimes associated with pain, and nobody likes pain. But the inflammatory response is also extremely important for wound healing and in clearing infection.
“We don’t want zero inflammation; we want appropriate inflammation,” he says. “If we want to heal wounds, inflammation is good because it starts the process of rebuilding vasculature. It recruits all kinds of cells that are regenerative to that site.”
The labs tested four basic hydrogel types—two with positive charge and two negative—to see what kind of inflammation they would trigger. They discovered that positively charged hydrogels triggered a much stronger inflammatory response than negatively charged ones.
“Among the positive materials, depending on the chemistry generating that charge, we can either generate a strong or a moderate inflammatory response,” Hartgerink says. “If you’re going for wound-healing, you really want a moderate response, and we saw that in one of the four materials.
“But if you want to go for a cancer treatment, the higher inflammatory response might be more effective,” he says. “For something like drug delivery, where inflammation is not helpful, one of the negatively charged materials might be better.
“Basically, we’re laying the groundwork to understand how to develop materials around the inflammatory responses these materials provoke. That will give us our best chance of success.”
Researchers at Texas Heart Institute (THI) helped analyze the cellular response to the hydrogels through multidimensional flow cytometry.
“The results of this work lay the groundwork for specifically tailoring delivery of a therapeutic by a delivery vehicle that is functionally relevant and predictable,” says Darren Woodside, vice president for research and director of the flow cytometry and imaging core at THI. “Aside from delivering drugs, these hydrogels are also compatible with a variety of cell types.
“One of the problems with stem cell therapies at present is that adoptively transferred cells don’t necessarily stay in high numbers at the site of injection,” he says. “Mixing these relatively inert, negatively charged hydrogels with stem cells before injection may overcome this limitation.”
Hartgerink says the work is foundational, rather than geared toward a specific application, but is important to the long-term goal of bringing synthetic hydrogels to the clinic.
“We have been speculating about a lot of the things we think are good and true about this material, and we now have more of a sound mechanistic understanding of why they are, in fact, true,” Hartgerink says.
The research appears in Biomaterials.
Additional coauthors are from Rice and the Texas Heart Institute. The National Institutes of Health, the Welch Foundation, the Mexican National Council for Science and Technology, the National Science Foundation, and a Stauffer-Rothrock Fellowship supported the research.
Source: Rice University
